SG11202102781UA - Chimeric antigen receptor - Google Patents
Chimeric antigen receptorInfo
- Publication number
- SG11202102781UA SG11202102781UA SG11202102781UA SG11202102781UA SG11202102781UA SG 11202102781U A SG11202102781U A SG 11202102781UA SG 11202102781U A SG11202102781U A SG 11202102781UA SG 11202102781U A SG11202102781U A SG 11202102781UA SG 11202102781U A SG11202102781U A SG 11202102781UA
- Authority
- SG
- Singapore
- Prior art keywords
- antigen receptor
- chimeric antigen
- chimeric
- receptor
- antigen
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/28—Expressing multiple CARs, TCRs or antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1815775.0A GB201815775D0 (en) | 2018-09-27 | 2018-09-27 | Chimeric antigen receptor |
| GBGB1902021.3A GB201902021D0 (en) | 2019-02-14 | 2019-02-14 | Chimeric antigen receptor |
| PCT/GB2019/052726 WO2020065330A2 (en) | 2018-09-27 | 2019-09-26 | Chimeric antigen receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202102781UA true SG11202102781UA (en) | 2021-04-29 |
Family
ID=68084861
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202102781UA SG11202102781UA (en) | 2018-09-27 | 2019-09-26 | Chimeric antigen receptor |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220033509A1 (en) |
| EP (1) | EP3856775A2 (en) |
| JP (2) | JP7458382B2 (en) |
| KR (1) | KR20210066865A (en) |
| CN (1) | CN112771076B (en) |
| AU (1) | AU2019348975A1 (en) |
| BR (1) | BR112021004986A2 (en) |
| CA (1) | CA3113896A1 (en) |
| CL (1) | CL2021000736A1 (en) |
| IL (1) | IL281428A (en) |
| MX (1) | MX2021003636A (en) |
| SG (1) | SG11202102781UA (en) |
| WO (1) | WO2020065330A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201317928D0 (en) * | 2013-10-10 | 2013-11-27 | Ucl Business Plc | Molecule |
| EP3662055A1 (en) * | 2017-08-02 | 2020-06-10 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| WO2024097992A2 (en) | 2022-11-04 | 2024-05-10 | Umoja Biopharma, Inc. | Particles displaying adhesion-molecule fusions |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011516041A (en) | 2008-03-12 | 2011-05-26 | イムクローン・リミテッド・ライアビリティ・カンパニー | Anti-TYRP1 antibody |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| WO2015069922A2 (en) | 2013-11-06 | 2015-05-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Alk antibodies, conjugates, and chimeric antigen receptors, and their use |
| KR101962524B1 (en) | 2013-11-21 | 2019-07-17 | 유씨엘 비즈니스 피엘씨 | Cell |
| GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| MX2017001011A (en) * | 2014-07-21 | 2018-05-28 | Novartis Ag | Treatment of cancer using humanized anti-bcma chimeric antigen receptor. |
| CA2956002C (en) * | 2014-07-24 | 2023-06-27 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
| GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
| CN116063565A (en) | 2014-12-05 | 2023-05-05 | 纪念斯隆-凯特琳癌症中心 | Chimeric antigen receptor targeting Fc receptor-like 5 and uses thereof |
| JP2018504894A (en) * | 2014-12-19 | 2018-02-22 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | Chimeric antigen receptor and method of use thereof |
| PL3560953T3 (en) | 2014-12-24 | 2024-05-13 | Autolus Limited | Cell |
| GB201501936D0 (en) | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| GB201504840D0 (en) | 2015-03-23 | 2015-05-06 | Ucl Business Plc | Chimeric antigen receptor |
| EP3283520B1 (en) * | 2015-04-13 | 2020-05-06 | Pfizer Inc | Chimeric antigen receptors targeting b-cell maturation antigen |
| CN108137669B (en) * | 2015-05-18 | 2023-02-17 | 优瑞科生物技术公司 | anti-ROR 1 chimeric antigen receptor |
| JP2018522833A (en) * | 2015-06-12 | 2018-08-16 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | Chimeric antigen receptor (CAR) constructs and disease treatment with T cells (CAR-T) or NK cells (CAR-NK) expressing CAR constructs |
| GB201514874D0 (en) * | 2015-08-20 | 2015-10-07 | Autolus Ltd | Cell |
| GB201514875D0 (en) | 2015-08-20 | 2015-10-07 | Autolus Ltd | Receptor |
| CA3001941A1 (en) | 2015-10-30 | 2017-05-04 | Nbe-Therapeutics Ag | Anti-ror1 antibodies |
| WO2017156479A1 (en) * | 2016-03-11 | 2017-09-14 | Bluebird Bio, Inc. | Ror1 chimeric antigen receptors |
| CN105777911B (en) * | 2016-04-12 | 2019-07-02 | 上海优卡迪生物医药科技有限公司 | Anti- BCMA Chimeric antigen receptor, encoding gene, recombinant expression carrier and its construction method and application |
| GB201801831D0 (en) * | 2018-02-05 | 2018-03-21 | Autolus Ltd | Chimeric receptor |
-
2019
- 2019-09-26 CN CN201980063392.7A patent/CN112771076B/en active Active
- 2019-09-26 CA CA3113896A patent/CA3113896A1/en active Pending
- 2019-09-26 JP JP2021516889A patent/JP7458382B2/en active Active
- 2019-09-26 US US17/279,874 patent/US20220033509A1/en active Pending
- 2019-09-26 BR BR112021004986-0A patent/BR112021004986A2/en unknown
- 2019-09-26 WO PCT/GB2019/052726 patent/WO2020065330A2/en active Application Filing
- 2019-09-26 KR KR1020217012340A patent/KR20210066865A/en unknown
- 2019-09-26 EP EP19779542.0A patent/EP3856775A2/en active Pending
- 2019-09-26 SG SG11202102781UA patent/SG11202102781UA/en unknown
- 2019-09-26 AU AU2019348975A patent/AU2019348975A1/en active Pending
- 2019-09-26 MX MX2021003636A patent/MX2021003636A/en unknown
-
2021
- 2021-03-11 IL IL281428A patent/IL281428A/en unknown
- 2021-03-24 CL CL2021000736A patent/CL2021000736A1/en unknown
-
2022
- 2022-05-17 US US17/746,642 patent/US20220356260A1/en active Pending
-
2023
- 2023-09-26 JP JP2023162990A patent/JP2023169370A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3856775A2 (en) | 2021-08-04 |
| CN112771076B (en) | 2024-04-02 |
| JP7458382B2 (en) | 2024-03-29 |
| CL2021000736A1 (en) | 2021-08-20 |
| CN112771076A (en) | 2021-05-07 |
| MX2021003636A (en) | 2021-07-21 |
| JP2023169370A (en) | 2023-11-29 |
| BR112021004986A2 (en) | 2021-06-08 |
| WO2020065330A3 (en) | 2020-05-14 |
| US20220356260A1 (en) | 2022-11-10 |
| JP2022502036A (en) | 2022-01-11 |
| IL281428A (en) | 2021-04-29 |
| KR20210066865A (en) | 2021-06-07 |
| WO2020065330A2 (en) | 2020-04-02 |
| US20220033509A1 (en) | 2022-02-03 |
| CA3113896A1 (en) | 2020-04-02 |
| AU2019348975A1 (en) | 2021-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276396A (en) | Chimeric antigen receptors targeting cd70 | |
| IL254254B (en) | Chimeric antigen receptor | |
| EP3732205A4 (en) | Multivalent chimeric antigen receptor | |
| GB201503742D0 (en) | Chimeric antigen receptor | |
| GB201607968D0 (en) | Chimeric antigen receptor | |
| GB201610512D0 (en) | Chimeric antigen receptor | |
| ZA202005837B (en) | Cd83-binding chimeric antigen receptors | |
| ZA201906321B (en) | Chimeric antigen receptor | |
| GB201807870D0 (en) | A CD79-specific chimeric antigen receptor | |
| IL279310A (en) | Cd79a chimeric antigen receptors | |
| IL281428A (en) | Chimeric antigen receptor | |
| IL285587A (en) | Hypoxia-responsive chimeric antigen receptors | |
| IL285909A (en) | Anti-bcma chimeric antigen receptors | |
| IL277946A (en) | Chimeric antigen receptor specific for interleukin-23 receptor | |
| GB201801831D0 (en) | Chimeric receptor | |
| GB201709508D0 (en) | Chimeric antigen receptor | |
| EP3585403A4 (en) | Tim3-binding chimeric antigen receptors | |
| GB201807862D0 (en) | Chimeric antigen receptor | |
| IL278992A (en) | Chimeric antigen receptor t cell therapy | |
| GB201519900D0 (en) | Chimeric antigen receptor | |
| GB201815775D0 (en) | Chimeric antigen receptor | |
| GB201809773D0 (en) | Chimeric antigen receptor | |
| GB201807866D0 (en) | Chimeric antigen receptor | |
| GB201906406D0 (en) | Chimeric antigen receptor | |
| GB201902021D0 (en) | Chimeric antigen receptor |